Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + tretinoin
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pembrolizumab + tretinoin is a **combination therapy** consisting of **pembrolizumab**, an immune checkpoint inhibitor (anti-PD-1 monoclonal antibody), and **tretinoin** (all-trans retinoic acid, ATRA), a vitamin A derivative. Pembrolizumab blocks the PD-1 pathway, thereby promoting T-cell-mediated anti-tumor immunity. Tretinoin targets myeloid-derived suppressor cells (MDSCs), reducing their frequency and suppressive function, thus enhancing anti-tumor immune responses when combined with pembrolizumab. This combination was investigated primarily for advanced melanoma. Clinical studies showed high response rates and durable complete responses in anti-PD-1 naïve advanced melanoma patients, with a favorable safety profile[1][2][3][5].
- Brand names
- KeytrudaVesanoid
- Other names
- pembrolizumab and tretinoinpembrolizumab and all-trans retinoic acidpembrolizumab + ATRA
02
Targets
RARA (Retinoic acid receptor alpha)RARB (Retinoic acid receptor beta)PDCD1 (Programmed cell death protein 1 receptor)RARG (Retinoic acid receptor gamma)
Beyond the preview
Go deeper on pembrolizumab + tretinoin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + tretinoin.